Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients

BACKGROUND: When tumour tissue is unavailable, cell-free DNA (cfDNA)can serve as a surrogate for genetic analyses. Because mutated alleles in cfDNA are usually below 1%, next-generation sequencing (NGS)must be narrowed to target only clinically relevant genes. In this proof-of-concept study, we deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Malapelle, Umberto, Mayo de-Las-Casas, Clara, Rocco, Danilo, Garzon, Monica, Pisapia, Pasquale, Jordana-Ariza, Nuria, Russo, Maria, Sgariglia, Roberta, De Luca, Caterina, Pepe, Francesco, Martinez-Bueno, Alejandro, Morales-Espinosa, Daniela, González-Cao, María, Karachaliou, Niki, Viteri Ramirez, Santiago, Bellevicine, Claudio, Molina-Vila, Miguel Angel, Rosell, Rafael, Troncone, Giancarlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Genetics & Genomics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355934/
https://www.ncbi.nlm.nih.gov/pubmed/28170370
http://dx.doi.org/10.1038/bjc.2017.8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355934/
https://www.ncbi.nlm.nih.gov/pubmed/28170370
http://dx.doi.org/10.1038/bjc.2017.8

Ejemplares similares